Webinar Date & Time: 15:00 GMT | 10:00 EST – Friday February 26
The emergence of more transmissible SARS-CoV-2 mutants and associated concerns about the effects of these mutations on the efficacy of vaccines has highlighted the vital importance of understanding the humoral immune response to SARS-CoV-2. But despite the advances in developing rapid tests to detect active infections, immunoassays have made only limited progress towards establishing a functional understanding of antibody-mediated immunity after infection or vaccination.
A major obstacle in obtaining this information has been the lack of tools that quantitively profile the molecular interactions via which neutralizing antibodies interfere with the binding of SARS-CoV-2 to host cells.
In our webinar we present a new type of rapid assay that is based on quantifying these protein interactions and provides functional insights equivalent to the gold standard cell-based neutralization assay by measuring the affinity, concentration, and neutralization potential of antibodies against the SARS-CoV-2 spike protein directly in serum. The webinar aims to cover:
- Why quantitative information on protein interactions is key to provide actionable insights on the potency of the immune response to SARS-CoV-2
- What are the drawbacks of the “gold standard” cell-based virus neutralization tests and why there is a need for a safe, rapid and easy-to use test
- How our technology is uniquely placed to rapidly assess the immune response to SARS-CoV-2 directly in serum
- How our novel affinity-based virus-neutralization assays could support the development of new vaccines and therapeutic antibodies, the investigation of new processes for tracking of functional immunity and vaccine escape and research into improvements in donor selection for convalescent plasma therapy
About the Speaker
Sebastian Fiedler (PhD)
Lead Application Scientist – Life Sciences
Sebastian Fiedler is a Lead Application Scientist – Life Sciences, at Fluidic Analytics in Cambridge (UK). Before joining Fluidic Analytics, he helped developing antibody therapeutics at the CRUK–AstraZeneca Antibody Alliance Laboratory, studied GPCR–lipid interactions during his postdoc at the University of Toronto and, during his PhD at the University of Kaiserslautern and at the Leibniz Institute of Molecular Pharmacology in Berlin he investigated how membrane proteins gain and retain their structures.
Find out more about Sebastian here.